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Background: Our aim was to examine whether comorbid mood and anxiety disorders influence patterns of treatment
or the perceived unmet need for treatment among those not receiving treatment for illegal drug use disorders.
Methods: Data came from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC, 2001–2002
and 2004–2005, n = 34,653). Lifetime DSM-IV illegal drug use disorder (abuse and dependence), as well as comorbid
mood (major depression, dysthymia, manic disorder, hypomanic disorder) and anxiety disorders (panic disorder,
agoraphobia, social phobia, specific phobia, generalized anxiety) were ascertained by a standardized psychiatric
interview. Treatment for illegal drug use disorders and perceived unmet need for treatment were assessed
among individuals with illegal drug use disorder. Odds of treatment and odds of perceived unmet need for
treatment were assessed using logistic regression, adjusting for socio-demographic characteristics, treatment for
mood and anxiety disorders, and comorbid alcohol use disorder.
Results: Out of 34,653 participants, 1114 (3.2%) had a diagnosis of lifetime illegal drug use disorder: 21.2% had a
comorbid mood disorder only, 11.8% a comorbid anxiety disorder only, and 45.9% comorbid mood and anxiety
disorders. Comorbid mood and anxiety disorders were not related to treatment for illegal drug use disorders
but were associated with an elevated likelihood of unmet need for treatment: compared to participants with no
comorbidities, multivariate ORs were 2.21 (95% CI: 1.23- 4.10) for mood disorder only, 2.38 (95% CI: 1.27-4.45) for
anxiety disorder only, and 2.90 (95% CI: 1.71-4.94) for both mood and anxiety disorders.
Conclusions: Individuals with an illegal drug use disorder and comorbid mood or anxiety disorders are
disproportionately likely to report unmet need for treatment. Integrated mental health and substance use
programs could prove effective in addressing their treatment needs.
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According to general population studies, approximately
7-10% of individuals suffer from an illegal drug use re-
lated disorder (abuse or dependence) during the course
of their lifetime [1]. Up to 53% of individuals with drug
abuse or dependence also have other psychiatric disor-
ders [2] and this group disproportionately experiences
poor health [3,4], low employment rates [5] and unstable
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reproduction in any medium, provided the orDespite evidence that adequate treatment can reduce
the severity and duration of symptoms and harm associ-
ated with illegal drug use disorders, only one third of
individuals with an illegal drug use disorder receive
treatment [5,6], which is less than in the case of other
psychiatric disorders such as alcohol abuse or depend-
ence, depression or anxiety disorders [7-12]. Untreated
illegal drug use disorders tend to relapse and can result
in hospitalizations as well as socio-economic problems
[13]. Factors associated with illegal drug use disorder
treatment include gender, ethnicity [14], employment
status, type of health insurance [15,16], family income,
number of drugs used [17] and a criminal record [14].
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nority (particularly African Americans in the United
States), are socioeconomically disadvantaged, have re-
stricted medical insurance, and reside in rural areas
[14,15,18-20]. In contrast, utilization of treatment for
illegal drug use disorders appears to be highest among
individuals who use multiple substances [21]. The co-
occurrence of illegal drug use disorders with mental
health difficulties is associated with an increased likeli-
hood of mental health treatment [22,23]. However,
treatment for illegal drug use disorders may be less fre-
quent, particularly in the presence of major depression
and anxiety [17,22,23].
Past studies on the role of psychiatric comorbidity
with regard to illegal drug use treatment have had a
number of limitations. First, they generally examined
treatment for alcohol and illegal drug disorders simul-
taneously, even though treatment rates and associated
factors may differ between these two forms of addiction
[24]. Second, they focused on the number, rather than
types, of psychiatric comorbidities, precluding specific
treatment recommendations [21]. Third, they did not
study reasons why some individuals with iillegal drug
use disorders did not receive treatment despite perceived
need [17,21].
In the present study, based upon data from the
National Epidemiologic Survey on Alcohol and Related
Conditions (NESARC), a nationally representative sample
of the US population, we examine the role of comorbid
mood and anxiety disorders with regard to treatment




We used data from the National Epidemiologic Survey
on Alcohol and Related Conditions (NESARC). Briefly,
this nationally representative study of the US population
was conducted in 2001–2002 and 2004–2005 among
non-institutionalized adults (≥18 years of age) residing
in households and group quarters. African-Americans,
Hispanics, and individuals aged 18–24 years were over-
sampled. All participants were interviewed at home by
trained lay interviewers who received extensive training
and supervision. After complete description of the study
to the participants, written informed consent was ob-
tained. All procedures, including informed consent, re-
ceived full ethical review and approval from the U.S.
Census Bureau and U.S. Office of Management and
Budget. Of the 43,093 respondents in 2001–2002, 34,653
were re-interviewed in 2004–2005. The response rate in
2001–2002 was 81% and 86.7% in 2004–2005 [25]. For
the present analysis we combined data from 2001–2002
and 2004–2005 and studied individuals with lifetimeillegal drug use disorders and their access to treatment.
Data were weighted at wave 2 to account for differential
loss to follow-up and to be representative of the target
population. This analysis includes 34,653 respondents
who completed interviews at wave 1 and wave 2.
Psychiatric disorders
Participants’ lifetime psychiatric disorders were measured
using the NIAAA Alcohol Use Disorder and Associated
Disabilities Interview Schedule (AUDADIS), a structured
interview designed to measure psychiatric disorders and
associated conditions in large scale surveys [17] in 2001–
2002 and 2004–2005. To meet criteria for a lifetime psychi-
atric diagnosis participants had to have a positive diagnosis
at either NESARC wave (or both). Lifetime illegal drug use
disorders were defined as abuse or dependence meeting
DSM-IV criteria [26] for any of the following illegal drugs:
opioids, sedatives, tranquilizers, amphetamine, cocaine, in-
halants/solvents, hallucinogens, cannabis, and heroin.
Lifetime mood disorders were defined as major de-
pression, dysthymia, manic disorder or hypomanic
disorder meeting DSM-IV criteria; lifetime anxiety dis-
orders were defined as panic disorder with or without
agoraphobia, agoraphobia with no history of panic dis-
order, social phobia, specific phobia, or generalized
anxiety meeting DSM-IV criteria [26].
Treatment for illegal drug use disorders
We divided the study population into four groups: 1) il-
legal drug use disorder without comorbid mood or anx-
iety disorders (n = 244), 2) illegal drug use disorder with
comorbid mood disorder only (n = 264), 3) illegal drug
use disorder with comorbid anxiety disorder only (n =
110), 4) illegal drug use disorder with comorbid mood
and anxiety disorders (n = 496).
Study outcomes
We examined two study outcomes: treatment for illegal
drug use disorders among all those with an illegal drug
use disorder and perceived unmet need for treatment
among those having not received treatment. Service use
was ascertained for each drug of abuse by the following
question: “Have you ever gone anywhere or seen anyone
for a reason that was related in any way to your use of
medicines or drugs - a physician, counselor, Narcotics
Anonymous, or any other community agency or profes-
sional?” Participants who answered positively were add-
itionally asked to describe the type of treatment they
received (outpatient, inpatient, detoxification, rehabilita-
tion, social services). Moreover, participants were asked
about perceived unmet need for treatment: “Was there
ever a time when you thought you should see a doctor,
counselor, or other health professional or seek any other
help for your drug use, but you didn’t go?” Participants
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were further asked about reasons for not receiving treat-
ment. Variables ascertaining treatment for illegal drug
use disorders and perceived unmet need for treatment
were dichotomized. For the purpose of our descriptive
analyses participants were split into four groups: 1) those
who had an illegal drug use disorder and received treat-
ment (n = 350); those with an illegal drug use disorder
who did not receive treatment (n = 764); 2) those who
did not receive treatment for an illegal drug use disorder
and perceived an unmet need for treatment (n = 127); 3)
those who did not receive treatment for an illegal drug
use disorder and did not perceive an unmet need for
treatment (n = 637).
Additionally, we studied access to treatment for illegal
drug use disorders in relation to the type and number of
drug of abuse.
Covariates
Socio-demographic covariates included sex (female vs.
male), age (35–54, ≥55 years vs. 18–34 years), educa-
tional level (<high school degree vs. ≥ high school),
marital status (divorced/separated, widowed, never mar-
ried vs. married), ethnicity (African American, Other
non-Caucasian vs. Caucasian) and family income dichot-
omized using the lowest quartile of the distribution as
the cut-off ($10,000-19000 vs. ≥$20,000/year).
Statistical analyses
Analyses examining the relationship between the pres-
ence of mood and anxiety disorders and a) treatment for
an illegal drug use disorder (n = 1114) and b) perceived
unmet need for treatment among participants who never
received treatment for an illegal drug use disorder (n =
764) were conducted separately.
Because of a significant overlap between treatment for
an illegal drug use disorder and treatment for mood
(44.5%) and anxiety (28.5%) disorders, in secondary ana-
lyses we further controlled for lifetime treatment for
mood and anxiety disorders. Furthermore, 74.9% of par-
ticipants with lifetime illegal drug use disorder also had
an alcohol-related disorder; in further analyses we con-
trolled for comorbid alcohol-related disorder.
All analyses were carried out in a logistic regression
framework using STATA/SE 12; odds ratios and 95%
confidence intervals were weighted to account for sam-
pling design. We used Taylor series estimation methods
for variance estimation (STATA 1svy1 commands) to
obtain proper standard error estimates for the cross-
tabulations and logistic regressions [27].
Results
Our study included 1,114 individuals with a lifetime his-
tory of an illegal drug use disorder (mean age 37.5 years,SD = 0.45). Table 1 describes characteristics of study par-
ticipants according to whether they received treatment
for an illegal drug use disorder or not, and if not, depending
on whether they reported a perceived unmet need for treat-
ment. Overall, participants were mostly male (62.1%), aged
35–54 years (49.2%), Caucasian (71.6%), had graduated
from high school (84.0%), had a family income ≥ 20,000 US
dollars/year (73.4%), and were not married (52.8%). The
majority used one (70.7%), two (17.2%) or three drugs
(4.3%). The most frequently used drugs were cannabis
(47.2%) and cocaine (22.6%). 21.2% of participants had a
comorbid mood disorder only, 11.8% a comorbid anxiety
disorder only, and 45.9% comorbid mood and anxiety
disorders.Psychiatric profile classification
As shown in Table 2, the most frequent types of treat-
ment were a consultation with a physician, psychiatrist,
psychologist or social worker (46.9%) and attendance of
a drug rehabilitation program (10.2%).
Overall, 31.4% of study participants ever received any
form of treatment for an illegal drug use disorder. As
shown in Table 3, the likelihood of receiving such treatment
was not associated with comorbid mood and anxiety disor-
ders. The probability of illegal drug use disorder treatment
was highest in participants who were older than 35 years
and lowest in participants who were Native American,
Asian, or Hispanic.
In additional analyses we observed that the majority of
participants who received treatment for illegal drug use
disorders used one (33.0%) or two drugs (14.0%) and the
number of drugs used was positively associated with
treatment (p < 0.01). Moreover, treatment was more fre-
quent among participants with a lifetime history of an
alcohol-related disorder (multivariate OR: 1.93, 95% CI
1.34- 2.78), as well as among those who received treat-
ment for mood disorders (multivariate OR: 1.72, 95% CI
1.13-2.61) or anxiety disorders (multivariate OR: 1.89,
95% CI 1.16-3.08).Perceived unmet treatment need
Eleven percent of study participants who did not receive
treatment reported unmet need for treatment for an il-
legal drug use disorder. As shown in Table 4, individuals
who simultaneously had an illegal drug use disorder and
a mood or anxiety disorder had higher levels of per-
ceived unmet need for treatment than participants with
no such comorbidities (bivariate ORs respectively: illegal
drug use and mood disorder: 2.17, 95% CI: 1.22-3.85; il-
legal drug use and anxiety disorder: 2.37, 95% CI: 1.25-
4.48; illegal drug use and mood and anxiety disorder:
2.74, 95% CI 1.66- 4.55). Other factors significantly asso-
ciated with perceived unmet need for treatment included









P-value Perceived unmet need
for treatment (n = 127)
No unmet need for











35-54 54.3 47.0 44.4 60.7
≥55 9.7 6.5 6.6 6.2
Education
<High school 14.4 16.5
0.39
16.7 15.4 0.93
≥ High school 85.6 83.5 83.3 84.6
Family income
$10 000–19,000 30.3 25.0
0.44
25.0 25.0 0.99










Black 10.3 10.8 9.9 15.2
Other 13.8 19.5 20.6 38.8
Type of illegal drug used
Cannabis 50.6 48.0 0.73 53.9 42.0 0.06
Cocaine 45.5 30.6 0.0003 27.8 45.2 0.003
Heroin 7.6 2.6 0.008 2.6 2.6 0.99
Tranquilizers 15.8 8.2 0.006 8.1 9.0 0.78
Opioids 20.7 17.6 0.35 17.9 15.8 0.66
Amphetamine 25.2 19.3 0.08 17.7 28.2 0.03
Sedatives 13.2 8.9 0.08 8.8 9.3 0.89
Hallucinogens 12.1 8.9 0.23 8.9 8.9 0.99
Inhalants/Solvents 2.73 1.4 0.28 1.5 0.9 0.59
Psychiatric profile





Illegal drug use disorder + mood disorders only 20.9 21.3 0.88 21.8 18.7 0.49
Illegal drug use disorder + anxiety disorders only 8.9 13.1 0.10 12.6 15.4 0.53
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of age.
After controlling for all socio-demographic covariates,
comorbid mood and anxiety disorders were associated
with an elevated likelihood of perceived unmet need fortreatment (multivariate ORs respectively: illegal drug use
and mood disorder: 2.21, 95% CI, 1.23- 4.10; illegal drug
use and anxiety disorder: 2.38, 95% CI, 1.27-4.45; illegal
drug use and mood and anxiety disorder: 2.90, 95% CI,
1.71-4.94). After adjusting for treatment for mood and
Table 2 Type of treatment for illegal drug use disorders
received, the NESARC, 2001/2002-2004/2005 (n = 350,
weighted %)
Types of treatment N %
Physician, psychiatrist, psychologist or social worker 258 46.9
Any other agency or professional 81 11.0
Drug rehabilitation 73 10.2
12-Step meeting 45 5.8
Clergy 33 5.1
Did not report the type of treatment 28 5.1
Emergency room 24 3.4
Halfway house 23 3.1
Employee assistance program 20 2.6
Outpatient clinic 14 1.9
Family or social services 11 1.8
Inpatient ward of psychiatric/general hospital or community
mental health
9 1.1
Drug detoxification ward or clinic 5 1.0
Methadone maintenance program 4 0.6
Crisis center 3 0.4
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use disorder as well as an anxiety disorder or both mood
and anxiety disorders had higher levels of perceived un-
met need for treatment than participants with no such
comorbidities (multivariate ORs respectively: illegal drug
use and anxiety disorder: 2.34, 95% CI: 1.23- 4.44; illegal
drug use and mood and anxiety disorders: 1.94, 95% CI:
1.09- 3.47).
After additionally controlling for lifetime alcohol-
related disorder, only comorbid anxiety disorder
remained significantly associated with an elevated likeli-
hood of perceived unmet need for treatment (multivari-
ate OR 2.02, 95% CI, 1.03-3.94).
Main reasons for not using treatment services were:
the drug problem not being serious enough (37.3%), no
willingness to seek treatment (20.0%), spontaneous recovery
(11.3%) and social stigma (7.7%) (not shown). These did
not differ between the three comorbidity groups (p = 0.15).
The majority of participants who reported perceived unmet
need for treatment used one (39.8%) or two (16.5%) drugs,
primarily cannabis (40.5%), cocaine (27.4%), or heroin
(7.4%). The number of drugs used was positively associated
with perceived unmet need for treatment (p <0.01).
Discussion
Main findings
Our study, based on a nationally representative sample
of the US adult population, shows that among individ-
uals who have an illegal drug use disorder, comorbid
mood and anxiety disorders are not associated withtreatment for illegal drug use disorders. However, com-
mon psychiatric comorbidities predict an over twofold
increase in perceived unmet need for treatment, which
is not accounted for by socio-demographic characteris-
tics, treatment for mood and anxiety disorders and co-
morbid alcohol use disorder. Overall, these findings
suggest that individuals who concomitantly have an il-
legal drug use disorder and mood or anxiety disorders
require special attention from mental health and addic-
tion specialists; integrated mental health and substance
use programs could prove effective in addressing their
treatment needs.
Treatment for illegal drug use disorders
Our result of no association between comorbid mood
and anxiety disorders and treatment for illegal drug use
disorders contrasts with findings of studies which simul-
taneously examined illegal drug use and alcohol-related
disorders [21]. However, in line with prior research, we
found that treatment for illegal drug use disorders was
associated with the number of drugs used [21], suggest-
ing that the severity of substance use problems is a rele-
vant predictor of treatment seeking.
Perceived unmet need for treatment
Mood and anxiety disorders were associated with high
levels of unmet need for illegal drug use disorder treat-
ment. Overall, the magnitude of the association was
similar whether the comorbid disorder was a mood or
an anxiety disorder, suggesting that it is the presence of
comorbidity rather than its type that is especially rele-
vant. After controlling for treatment for mood and anx-
iety disorders as well as comorbid alcohol use disorder,
only anxiety disorders were associated with an approxi-
mately two-fold increase in the likelihood of perceived
unmet need for treatment. One possible explanation of
this finding is that individuals who simultaneously have
illegal drug use problems and mood disorders seek treat-
ment for their mood disorder, because of lesser stigma,
easier access, and simpler reimbursement schemes [21].
This does not appear to be the case of participants with
comorbid anxiety disorders, who are less likely to seek
mental health treatment.
Elevated rates of perceived unmet need for treatment
for illegal drug use related disorders may be due to the
scarcity of specialized services, absence of adequate pro-
grams for simultaneous treatment of co-occurring illegal
drug use and psychiatric disorders, as well as stigma.
Moreover, perceptions of the severity of the drug use
problem and of treatment effectiveness may also play a
role. Currently available treatment services for people
who have illegal drug use problems other than crack/
heroin may not be sufficient, leading to low access and
high perceived unmet need for treatment. Furthermore,
Table 3 Treatment for illegal drug use disorders in relation to comorbid mood or anxiety disorders, the NESARC, 2001/
2002-2004/2005, n = 1114 (weighted OR, 95% CI)
Bivariate OR 95% CI Adjusted ORa 95% CI
Psychiatric profile
Illegal drug disorder + neither mood nor anxiety disorder 1 1
Illegal drug disorder + mood disorder only 1.15 0.70-1.90 1.21 0.73-2.01
Illegal drug disorder + anxiety disorder only 0.80 0.43- 1.50 0.75 0.40-1.40
Illegal drug disorder + mood and anxiety disorder 1.39 0.94- 2.05 1.47 0.98- 2.19
Sex
Male 1 1
Female 0.50 0.43-0.67 0.73 0.51-1.03
Age
18-34 1 1
35-54 1.01 0.79-1.29 1.46 1.03- 2.06
≥55 0.26 0.18-0.36 1.97 1.09-3.56
Educational level
<High school 1 1
≥ High school 0.97 0.72-1.29 1.29 0.77-2.16
Family income
$10 000–19,000 1 1
≥$20 000 1.75 1.41- 2.18 1.52 0.99- 2.35
Marital status
Married 1 1
Not married 1.65 1.34-2.04 0.79 0.57-1.11
Ethnicity
White 1 1
Black 0.89 0.70- 1.14 0.93 0.59-1.47
Other 0.82 0.63 -1.07 0.65 0.41-0.02
aOdds ratios are weighted to account for sampling design and adjusted for all covariates described in the table.
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mental health services not specialized in addiction, indi-
viduals may have the impression that their drug use
problems are not serious enough to require treatment or
that adequate treatment is not available.
Limitations and strengths
We need to acknowledge several study limitations. First, il-
legal drug use and psychiatric disorders, as well as treat-
ment for illegal drug use disorder and perceived unmet
need for treatment were studied over participants’ lifetime
and we are not able to assess trajectories of substance use
and treatment. Research shows that the association be-
tween addictive behaviors and mood and anxiety disorders
is bidirectional, but common psychiatric disorders most fre-
quently precede onset of substance dependence [28]. Thus,
in our study mood and anxiety disorders probably preceded
treatment for illegal drug use disorders. Second, data on il-
legal drug use were collected by federal employees andcould be underreported. Nonetheless, the NESARC study
interviews were confidential and the reliability of the
AUDADIS-IV is good to excellent, therefore the influence
of information bias on our measures should be limited
[29-31]. Prior to fieldwork, Census employees received ex-
tensive training in the AUDADIS, which was created to be
administered by non-clinicians, similar to several standard-
ized epidemiological interviews [30]. Moreover, the reliabil-
ity of the AUDADIS have previously been verified and
described [31]. Third, access to treatment for illegal drug
use disorders and unmet need for treatment were ascer-
tained using a single measure specific to the NESARC
study, previously used by other researchers [32]. Fourth, the
study population did not include individuals who are insti-
tutionalized, who may have elevated rates of both illegal
drug use disorders and unmet treatment needs. Therefore,
the association between mood and anxiety disorders and
unmet need for illegal drug use treatment may be stronger
than we report. Fifth, we were not able to examine whether
Table 4 Unmet need for illegal drug use disorders treatment in relation to comorbid mood and anxiety, NESARC,
2001/2002-2004/2005, n = 764 (weighted OR, 95% CI)
OR bivariate 95% CI Adjusted ORb 95% CI
Psychiatric profile
Illegal drug disorder + no mood or anxiety disorder 1 1
Illegal drug disorder + mood disorder only 2.17 1.22- 3.85 2.21 1.23- 4.10
Illegal drug disorder + anxiety disorder only 2.37 1.25- 4.48 2.38 1.27-4.45
Illegal drug disorder + mood and anxiety disorder 2.74 1.66- 4.55 2.90 1.71-4.94
Sex
Male 1 1
Female 0.54 0.43- 0.67 0.87 0.59-1.29
Age
18-34 1 1
35-54 1.22 0.94-1.57 1.83 1.3- 2.57
≥55 0.17 0.11-0.27 1.36 0.71- 2.59
Educational level
<High school 1 1
≥ High school 0.91 0.63-1.31 1.44 0.77- 2.70
Family income
$10 000–19,000 1 1
≥$20 000 1.53 1.17- 2.001 1.21 0.77-1.9
Marital status
Married 1 1
Not married 1.61 1.24- 2.08 1.02 0.72-1.45
Ethnicity
White 1 1
Black 1.17 0.86-1.59 1.63 1.02-2.6
Other 0.98 0.73-1.32 0.96 0.61-1.52
bOdds ratios are weighted to account for sampling design and adjusted for all covariates described in the table.
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tween rural and urban areas, by state, or type of treatment
unit.
Our study also has strengths. First, we studied a na-
tionally representative sample of the US adult population
which limits the possibility of selection bias. Second,
psychiatric disorders were assessed using a structured
diagnostic questionnaire, which evaluates the presence
of clinically relevant disorders as measured by DSM-IV
criteria [26]. Third, we investigated factors associated
with service use, but also unmet perceived need for
treatment for illegal drug related disorders.
Integrated treatment of comorbid illegal drug disorders
and mental health problems
National surveys indicate that only half of US mental
health centers offer treatment programs for individuals
with ‘dual diagnosis’ and this proportion did not signifi-
cantly change during the past decade [6]. Lack of pro-
gress in this area can be explained by a) insufficientclinical knowledge, b) the absence of standardized
screening procedures to identify individuals who have an
illegal drug use disorder [33,34], and c) incomplete treat-
ment guidelines in case of dual diagnosis and insufficient
organizational support [35]. Patients themselves repeat-
edly report that illegal drug use disorders are often ig-
nored and not treated by mental health care providers.
According to a proposed four-quadrant continuity-of-
care model, a) persons with low severity psychiatric and
substance use disorders should be treated in the primary
health care system (quadrant I); b) persons with high se-
verity psychiatric disorders and low severity substance
use disorders should be treated in the mental health sys-
tem (quadrant I); c) persons with low severity psychiatric
disorders and high severity substance use disorders
should be treated in the addiction treatment system
(quadrant III); d) persons with high severity psychiatric
and substance use disorders need to use multiple treat-
ment systems and make more frequent use of emergency
and inpatient services (quadrant IV) [36]. This relies on
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tween the point-of-contact (primary care, emergency de-
partments, etc.) and specialized care. Number of studies
conducted in the last 15 years provided evidence for the
effectiveness of integrated treatment for comorbid psychi-
atric and substance use disorders [37-39]. Nevertheless the
integration of mental health and substance use treatment
services has produced uneven results due to a number of
barriers such as the absence of regulations, the lack of ap-
propriate financial resources [40], the lack of sufficiently ex-
perienced staff [41], high rates of stuff turn over [42], and
the lack of tools and implementation strategies [43]. In a
context of low availability of integrated treatment, progress
has been made with the development and continued valid-
ation of external rating tools (DDCAT -the Dual Diagnosis
Capability in Addiction Treatment and DDCMHT-the
Dual Diagnosis Capability in Mental Health Treatment) to
determine the capability of substance abuse and mental
health service providers to treat co-occurring disorders
[44,45]. Previous evaluations using the DDCAT showed
that the majority of substance abuse programs were rated
less than ‘capable’ and only few programs achieved or
exceeded the ‘capable’ level [46,47]. Overall, growing evi-
dence stresses the importance of routine screening for il-
legal drug use disorders in patients with other psychiatric
disorders and the integration of addiction services into psy-
chiatric and medical treatment settings to promote symp-
tom reduction and stable remission.
Conclusions
Our study suggests that the presence of comorbid mood
and anxiety disorders is associated with an increased
likelihood of perceived unmet need for treatment for il-
legal drug use disorders, which should be brought to cli-
nicians’ attention. The presence of mood and anxiety
disorders should increase awareness of a potential illegal
drug use disorder which also requires treatment. In
terms of public health, our findings imply that integrated
treatment services that provide combined treatment for
illegal drug use disorders and mental health problems
could also help improve treatment of patients with dual
diagnosis.
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